3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
1
Neoplasms
1
Gallbladder Neoplasms
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Interventions
Gemcitabine
4
Cisplatin
4
Capecitabine
4
Oxaliplatin
3
Leucovorin
2
Fluorouracil
2
Albumin-Bound Paclitaxel
2
titanium silicide
1
tegafur-gimeracil-oteracil
1
surufatinib
1
pembrolizumab
1
mitazalimab
1
durvalumab
1
cediranib
1
anlotinib
1
Taxes
1
S 1 (combination)
1
Paclitaxel
1
Folfox protocol
1
Control Groups
1
ARRY-334543
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Biliary Tract Neoplasms
×
ARRY-334543
×
Clear all
NCT03093870
2021-08-03
TreeTopp
ASLAN Pharmaceuticals
Phase 2/3
Completed
151 enrolled
18 charts